J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off
This article was originally published in The Tan Sheet
Executive Summary
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market
You may also be interested in...
NSAID, Antihistamine Use More Affected By Copay Raise Than Other Rxs – Study
Consumer spending on prescription non-steroidal anti-inflammatories and antihistamines decreased 45% and 44%, respectively, when insurance copays for the products doubled, according to a study published in the Journal of the American Medical Association May 19
NSAID, Antihistamine Use More Affected By Copay Raise Than Other Rxs – Study
Consumer spending on prescription non-steroidal anti-inflammatories and antihistamines decreased 45% and 44%, respectively, when insurance copays for the products doubled, according to a study published in the Journal of the American Medical Association May 19
NSAID, Antihistamine Use More Affected By Copay Raise Than Other Rxs – Study
Consumer spending on prescription non-steroidal anti-inflammatories and antihistamines decreased 45% and 44%, respectively, when insurance copays for the products doubled, according to a study published in the Journal of the American Medical Association May 19
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: